Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 29, 2022 - Issue 1
Submit an article Journal homepage
276
Views
1
CrossRef citations to date
0
Altmetric
Articles

Utilization and tolerance of beta-blockers among patients with AL amyloidosis

Alexandros BriasoulisDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, GreeceCorrespondence[email protected]
,
Kimon StamatelopoulosDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
,
Ioannis PetropoulosDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
,
Raphael PatrasDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
,
Foteini TheodorakakouDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
,
Maria GavriatopoulouDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, GreeceORCID Iconhttps://orcid.org/0000-0002-6244-1229
ORCID Icon,
Argyrios NtalianisDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
,
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
&
Efstathios KastritisDepartment of Clinical Therapeutics, National Kapodistrian University of Athens, Medical School, Athens, Greece
 show all
Pages 31-37 | Received 03 Jan 2021, Accepted 13 Sep 2021, Published online: 22 Sep 2021

References

  • Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci. 2019;4(3):438–448.
  • Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
  • Tuzovic M, Yang EH, Baas AS, et al. Cardiac amyloidosis: diagnosis and treatment strategies. Cur Onc Rep. 2017;19(7):46.
  • Beck-da-Silva L, de Bold A, Davies R, et al. Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure. Congest Heart Fail. 2004;10(3):127–132.
  • Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management. JACC Cardiooncol. 2019;1(1):117–130.
  • Aimo A, Vergaro G, Castiglione V, et al. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med. 2020;80:66–72.
  • Wechalekar AD, Schonland SO, Kastritis E, et al. A 18 European collaborative study of treatment outcomes in 346 patients with cardiac stage iii al amyloidosis. Blood. 2013;121(17):3420–3427.
  • Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–23125.
  • Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
  • Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26–35.
  • Yum B, Archambault A, Levitan EB, et al. Indications for β-blocker prescriptions in heart failure with preserved ejection fraction. J Am Geriatr Soc. 2019;67(7):1461–1466.
  • Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620.
  • Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(25):3042–3051.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.